Newsroom | 36780 results

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) heeft vandaag bekendgemaakt dat de Europese Commissie (EC) Zynyz® (retifanlimab) in combinatie met carboplatine en paclitaxel (op platina gebaseerde chemotherapie) heeft goedgekeurd voor de eerstelijnsbehandeling van volwassen patiënten met gemetastaseerd of inoperabel lokaal recidiverend plaveiselcelcarcinoom van het anale kanaal (SCAC). Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp...

WILMINGTON, Delaware--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) anunció hoy que la Comisión Europea ha aprobado Zynyz® (retifanlimab) en combinación con carboplatino y paclitaxel (quimioterapia basada en platino) para el tratamiento de primera línea de pacientes adultos con carcinoma de células escamosas del canal anal avanzado metastásico o inoperable que recidiva localmente. El comunicado en el idioma original es la versión oficial y autorizada del mismo. Esta traducción es solamente un medio de...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces the European Commission Approval of Zynyz (retifanlimab) for First-Line Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)...

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (NASDAQ: HYFT), a bio-native AI company, today announced B Cell Llama™, a platform for the discovery of VHH nanobodies: the single-domain antibody fragments increasingly recognized as the ideal molecular building blocks for bispecific antibodies, multispecific therapeutics, and CAR-T cell therapies. Bispecific antibody sales alone are projected to reach US$50 billion by 2030, with the broader cell therapy market adding tens of billions mor...

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (NASDAQ : HYFT), une société d'IA bio-native, a présenté aujourd'hui B Cell Llama™, une plateforme de découverte de nanocorps VHH : les fragments d'anticorps à domaine unique de plus en plus considérés comme étant de parfaits éléments constitutifs moléculaires des anticorps bispécifiques, les thérapies multispécifiques et les thérapies cellulaires CAR-T. Les ventes d'anticorps bispécifiques devraient atteindre 50 milliards de dollars améri...

CHICAGO--(BUSINESS WIRE)--The Andrew Weishar Foundation collaborated in a volunteer initiative alongside the SBB Research Group Foundation, which partners with local nonprofits through its Champion A Charity Program. For the third year, the SBB Research Group Foundation partnered with The Andrew Weishar Foundation, an organization dedicated to easing the financial and emotional burdens of families facing serious medical challenges, to provide holiday support for five families. Volunteers wrappe...

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter and year ended December 31, 2025, and provides an operational update. “During our fourth quarter and throughout 2025, we continued to deliver strong commercial performance, su...

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on March 2, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 282,000 shares of common stock to seven new employees under the Company’s 2024 Induc...

NASHVILLE, Tennessee et MENLO PARK, Californie--(BUSINESS WIRE)--Mosaic Clinical Technologies™, une filiale en propriété exclusive de Radiology Partners, est heureuse d’annoncer que Cognita™, son unité commerciale d’IA développant des modèles génératifs de vision-langage (VLM) pour la radiologie, a reçu la désignation de Breakthrough Device de l’U.S. Food and Drug Administration (FDA) pour Cognita Chest X-Ray (CXR)™1 dans plusieurs indications critiques. Cognita CXR est le premier modèle généra...

NASHVILLE, Tennessee, und MENLO PARK, Kalifornien, USA--(BUSINESS WIRE)--Mosaic Clinical Technologies™, eine hundertprozentige Tochtergesellschaft von Radiology Partners, gibt bekannt, dass Cognita™ – der Geschäftsbereich für künstliche Intelligenz, der generative Vision-Language-Modelle (VLMs) für die Radiologie entwickelt – von der US-amerikanischen Arzneimittelbehörde FDA (Food and Drug Administration) den Status „Breakthrough Device“ für Cognita Chest X-Ray (CXR)™1 für mehrere kritische Ind...